TerminatedPhase 4

Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis

Stopped: lack of inclusion pandemic, investigator reluctance, lower than expected incidence of infection

France103 participantsStarted 2018-02-08

Plain-language summary

Antimicrobial treatment could be beneficial in patients with ventilator-associated tracheobronchitis (VAT). The hypothesis of this study is that antibiotic treatment for VAT (3 or 7 days), compared with no antibiotic treatment, would reduce the incidence of transition from VAT to ventilator-associated pneumonia (VAP).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. absence of new infiltrate on chest X ray
✓. two of the three following conditions: fever \> 38.5 °C or \<36.5, leucocyte count \> than 12 000 cells per μL or \<than 4000 cells per μL purulent tracheal secretions
✓. and positive tracheal aspirate (≥105 cfu/mL)

What they're measuring

The percentage of patients with a transition from VAT to VAP,

Timeframe: from randomization to day 28 (4 weeks)

Trial details

NCT IDNCT03012360

SponsorUniversity Hospital, Lille

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-07-07

View on ClinicalTrials.gov More Mechanical Ventilation Complication trials